Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments.

Cameron EJ, McSharry C, Chaudhuri R, Farrow S, Thomson NC.

Clin Exp Allergy. 2012 Sep;42(9):1302-12. doi: 10.1111/j.1365-2222.2012.03979.x. Review.

PMID:
22925316
2.

Chronic macrolide therapy in inflammatory airways diseases.

Friedlander AL, Albert RK.

Chest. 2010 Nov;138(5):1202-12. doi: 10.1378/chest.10-0196. Review.

PMID:
21051396
3.
5.

The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases.

Eraković Haber V, Bosnar M, Kragol G.

Future Med Chem. 2014 Apr;6(6):657-74. doi: 10.4155/fmc.14.14. Review.

PMID:
24895894
6.

Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.

Altenburg J, de Graaff CS, van der Werf TS, Boersma WG.

Respiration. 2011;81(1):75-87. doi: 10.1159/000320320. Epub 2010 Aug 21. Review.

PMID:
20733282
7.

Role of long term antibiotics in chronic respiratory diseases.

Suresh Babu K, Kastelik J, Morjaria JB.

Respir Med. 2013 Jun;107(6):800-15. doi: 10.1016/j.rmed.2013.02.009. Epub 2013 Mar 20. Review.

8.

Macrolides and airway inflammation in children.

Shinkai M, Rubin BK.

Paediatr Respir Rev. 2005 Sep;6(3):227-35. Review.

PMID:
16153572
9.

Long-term macrolide treatment for chronic respiratory disease.

Spagnolo P, Fabbri LM, Bush A.

Eur Respir J. 2013 Jul;42(1):239-51. doi: 10.1183/09031936.00136712. Epub 2012 Nov 22. Review.

10.
11.

Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.

López-Boado YS, Rubin BK.

Curr Opin Pharmacol. 2008 Jun;8(3):286-91. doi: 10.1016/j.coph.2008.01.010. Epub 2008 Mar 12. Review.

PMID:
18339582
12.

Clinical implications of the immunomodulatory effects of macrolides.

Tamaoki J, Kadota J, Takizawa H.

Am J Med. 2004 Nov 8;117 Suppl 9A:5S-11S. Review.

PMID:
15586558
13.

Anti-inflammatory effects of macrolides in childhood lung diseases.

Luisi F, Gandolfi TD, Daudt AD, Sanvitto JP, Pitrez PM, Pinto LA.

J Bras Pneumol. 2012 Nov-Dec;38(6):786-96. Review. English, Portuguese.

14.

[Macrolides. Antiinflammatory and immunomodulator effects. Indication in respiratory diseases].

Sacre Hazouri JA.

Rev Alerg Mex. 2006 May-Jun;53(3):108-22. Review. Spanish.

PMID:
16970113
15.

Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K.

Eur J Clin Pharmacol. 2012 May;68(5):479-503. doi: 10.1007/s00228-011-1161-x. Epub 2011 Nov 22. Review.

PMID:
22105373
16.

Macrolides in cystic fibrosis.

Bell SC, Senini SL, McCormack JG.

Chron Respir Dis. 2005;2(2):85-98. Review.

PMID:
16279156
17.

Macrolide antibiotics, bacterial populations and inflammatory airway disease.

Swords WE, Rubin BK.

Neth J Med. 2003 Jul;61(7):242-8. Review.

18.

Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators.

Giamarellos-Bourboulis EJ.

Int J Antimicrob Agents. 2008 Jan;31(1):12-20. Epub 2007 Nov 1. Review.

PMID:
17935949
19.

Long-term macrolide therapy in chronic inflammatory airway diseases.

Crosbie PA, Woodhead MA.

Eur Respir J. 2009 Jan;33(1):171-81. doi: 10.1183/09031936.00042208. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk